Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 6/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.57 |
| ▸ | NPC1 | O15118 | 5/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.57 |
| ▸ | MAPT | P10636 | 4/20 | 0.54 |
| ▸ | HPGD | P15428 | 4/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.52 |
| ▸ | GLA | P06280 | 1/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.52 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.52 |
| ▸ | RELA | Q04206 | 1/20 | 0.52 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 3/20 | 0.48 |
| ▸ | HPGDS | O60760 | 1/20 | 0.46 |
| ▸ | ALKBH2 | Q6NS38 | 1/20 | 0.46 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1194458 | 0.89 | NPC1 (0.59) | RAB9AALDH1A1NPC1SMN1; SMN2MAPT | |
| SCHEMBL8341099 | 0.89 | NPC1 (0.59) | RAB9ANPC1SMN1; SMN2MAPTKDM4E | |
| SCHEMBL24303776 | 0.89 | PTGDR2 (0.52) | RAB9AALDH1A1NPC1SMN1; SMN2MAPT | |
| SCHEMBL31420340 | 0.89 | HPGDS (0.55) | RAB9AALDH1A1NPC1SMN1; SMN2HPGD | |
| SCHEMBL4447424 | 0.89 | LMNA (0.58) | RAB9AALDH1A1NPC1SMN1; SMN2MAPT | |
| SCHEMBL2411096 | 0.88 | HPGDS (0.62) | RAB9AALDH1A1NPC1SMN1; SMN2MAPT | |
| SCHEMBL9034514 | 0.87 | MEN1 (0.57) | RAB9AALDH1A1NPC1SMN1; SMN2MAPT | |
| SCHEMBL12571565 | 0.87 | MAPK1 (0.49) | RAB9AALDH1A1NPC1SMN1; SMN2MAPT | |
| SCHEMBL6532816 | 0.86 | EGLN1 (0.46) | RAB9AALDH1A1NPC1SMN1; SMN2HPGD | |
| SCHEMBL6156135 | 0.86 | RAB9A (0.51) | RAB9AALDH1A1NPC1SMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240308989-A1 | PYRAN DERIVATIVES AS CYP11A1 (CYTOCHROME P450 MONOOXYGENASE 11A1) INHIBITORS | ORION CORP (FI) | 2024-09-19 | — | — | US | disclosed |
| US-12030871-B2 | Pyran dervatives as CYP11A1 (cytochrome P450 monooxygenase 11A1) inhibitors | ORION CORPORATION (FI) | 2024-07-09 | — | — | US | disclosed |
| US-20230286928-A1 | HETEROCYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF DISEASE | EPIGEN BIOSCIENCES, INC. (US) | 2023-09-14 | — | — | US | disclosed |
| CN-116162084-A | Pyran derivatives as CYP11A1 inhibitors | 奥赖恩公司 | 2023-05-26 | — | — | CN | disclosed |
| CN-110139861-B | Pyran derivatives as CYP11A1 (cytochrome P450 monooxygenase 11A 1) inhibitors | 奥赖恩公司 | 2022-12-30 | — | — | CN | disclosed |
| US-20210347765-A1 | PYRAN DERVATIVES AS CYP11A1 (CYTOCHROME P450 MONOOXYGENASE 11A1) INHIBITORS | ORION CORPORATION | 2021-11-11 | — | — | US | disclosed |
| EP-3558981-B1 | PYRAN DERIVATIVES AS CYP11A1 (CYTOCHROME P450 MONOOXYGENASE 11A1) INHIBITORS | ORION CORP (FI) | 2021-05-26 | — | — | EP | disclosed |
| US-20200299280-A1 | PYRAN DERVATIVES AS CYP11A1 (CYTOCHROME P450 MONOOXYGENASE 11A1) INHIBITORS | ORION CORP (FI) | 2020-09-24 | — | — | US | disclosed |
| US-10717726-B2 | Pyran dervatives as CYP11A1 (cytochrome P450 monooxygenase 11A1) inhibitors | ORION CORPORATION (FI) | 2020-07-21 | — | — | US | disclosed |
| EP-3558981-A1 | PYRAN DERVATIVES AS CYP11A1 (CYTOCHROME P450 MONOOXYGENASE 11A1) INHIBITORS | Orion Corporation (FI) | 2019-10-30 | — | — | EP | disclosed |
| WO-2018115591-A1 | PYRAN DERVATIVES AS CYP11A1 (CYTOCHROME P450 MONOOXYGENASE 11A1) INHIBITORS | ORION CORPORATION (FI) | 2018-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10717726-B2 | Pyran dervatives as CYP11A1 (cytochrome P450 monooxygenase 11A1) inhibitors | CYP11B1, CYP11B2, CYP4A11 | RAB9A 1542/4885ALDH1A1 133/4885NPC1 1874/4885 |
| US-20210347765-A1 | PYRAN DERVATIVES AS CYP11A1 (CYTOCHROME P450 MONOOXYGENASE 11A1) INHIBITORS | CYP11B1, CYP11B2, CYP4A11 | RAB9A 1542/4885ALDH1A1 133/4885NPC1 1874/4885 |
| US-12030871-B2 | Pyran dervatives as CYP11A1 (cytochrome P450 monooxygenase 11A1) inhibitors | CYP11B1, CYP11B2, CYP4A11 | RAB9A 1542/4885ALDH1A1 133/4885NPC1 1874/4885 |
| US-20240308989-A1 | PYRAN DERIVATIVES AS CYP11A1 (CYTOCHROME P450 MONOOXYGENASE 11A1) INHIBITORS | CYP11B1, CYP11B2, CYP4A11 | RAB9A 2222/4885ALDH1A1 161/4885NPC1 1802/4885 |
| US-20230286928-A1 | HETEROCYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF DISEASE | LPAR1, LPAR2, LPAR4 | RAB9A 1123/4885ALDH1A1 2298/4885NPC1 302/4885 |
| US-20200299280-A1 | PYRAN DERVATIVES AS CYP11A1 (CYTOCHROME P450 MONOOXYGENASE 11A1) INHIBITORS | CYP11B1, CYP11B2, CYP4A11 | RAB9A 1542/4885ALDH1A1 133/4885NPC1 1874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.